No Data
Express News | Zenas Biopharma Inc Says Bristol-Myers Squibb Co, Xencor Inc Are Among 5% or Greater Stockholders in the Company
Leerink Partners Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $32
Buy Rating Affirmed for Xencor on Promising XmAb819 Developments and Strong Strategic Position
Express News | Xencor Inc : Leerink Partners Raises Target Price to $32 From $29
Xencor (NASDAQ:XNCR) Shareholders Are up 6.7% This Past Week, but Still in the Red Over the Last Five Years
Express News | Xencor Inc : BofA Global Research Cuts Price Objective to $32 From $34